Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Sep 26, 2025; 17(9): 109715
Published online Sep 26, 2025. doi: 10.4252/wjsc.v17.i9.109715
Published online Sep 26, 2025. doi: 10.4252/wjsc.v17.i9.109715
Exploring the critical therapeutic window: Dose-frequency optimization of human umbilical cord mesenchymal stem cells for preclinical asthma treatment
Qiong-Hua Chen, Jing-Yang Zheng, The Graduate School of Fujian Medical University, Fuzhou 350122, Fujian Province, China
Qiong-Hua Chen, Jing-Yang Zheng, Jun-Yao Zhang, Chun-Yan Lin, Xue-E Zhuang, Department of Respiratory Medicine, Quanzhou Maternal and Child Health Hospital (Quanzhou Children’s Hospital), Quanzhou 362000, Fujian Province, China
Yu-Qin Zhu, Department of Pathology, Quanzhou Maternal and Child Health Hospital (Quanzhou Children’s Hospital), Quanzhou 362000, Fujian Province, China
Jing Cheng, Animal Experimental Centre, Quanzhou Medical College, Quanzhou 362000, Fujian Province, China
Xiao-Yi Huang, Department of Pharmacology, Quanzhou Medical College, Quanzhou 362000, Fujian Province, China
Author contributions: Chen QH contributed to the funding acquisition, writing-review & editing and supervision of this manuscript; Zheng JY revised and supervised the manuscript; Chen QH, Zhu YQ, Zhang JY, Cheng J, and Huang XY carried out the experiments; Chen QH, Zheng JY, Zhu YQ, Zhang YJ, Lin CY, and Zhuang XE analyzed the data.
Supported by the Joint Innovation Project Funds of Huaqiao University, No. 2022YX001.
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Quanzhou Children’s Hospital Institutional Review Board [Approval No. 2022(41)].
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at cqionghua283@163.com .
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qiong-Hua Chen, The Graduate School of Fujian Medical University, No. 1 Xuefu North Road, Shangjie Town, Minhou County, Fuzhou 350122, Fujian Province, China. cqionghua283@163.com
Received: May 19, 2025
Revised: June 17, 2025
Accepted: August 29, 2025
Published online: September 26, 2025
Processing time: 128 Days and 2.8 Hours
Revised: June 17, 2025
Accepted: August 29, 2025
Published online: September 26, 2025
Processing time: 128 Days and 2.8 Hours
Core Tip
Core Tip: This study reports, human umbilical cord blood-derived mesenchymal stem cell (HUC-MSC) therapy shows potential for treating asthma with high purity. HUC-MSC has been demonstrated to modulate airway remodeling, enhance lung function, and inhibit the inflammatory response in acute ovalbumin-induced asthma model. This study provides appropriate reference dosages to explore the possible intervention of HUC-MSC further. A single dosage of 2 × 105 cells is optimal, while double treatments with 2 × 105 cells may be optimal in reducing airway obstruction, but not for modulating airway inflammation.